CELEX 02006R1907 · v20251023

8.   TOXICOLOGICAL INFORMATION

COLUMN 1

STANDARD INFORMATION REQUIRED

COLUMN 2

SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1

▼M36

8.1.  Skin corrosion/irritation

8.1.  The study/ies do(es) not need to be conducted if:

— the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5) and the available information indicates that it should be classified as skin corrosion (Category 1), or

— the substance is spontaneously flammable in air or in contact with water or moisture at room temperature, or

— the substance is classified as acute toxicity by the dermal route (Category 1), or

— an acute toxicity study by the dermal route does not indicate skin irritation up to the limit dose level (2 000  mg/kg body weight).

If results from one of the two studies under point 8.1.1 or 8.1.2 already allow a conclusive decision on the classification of a substance or on the absence of skin irritation potential, the second study need not be conducted.

8.1.1.  Skin corrosion, in vitro

 

8.1.2.  Skin irritation, in vitro

 

8.2.  Serious eye damage/eye irritation

8.2.  The study/ies do(es) not need to be conducted if:

— the substance is classified as skin corrosion, leading to classification as serious eye damage (Category 1), or

— the substance is classified as skin irritation and the available information indicates that it should be classified as eye irritation (Category 2), or

— the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5) and the available information indicates that it should be classified as serious eye damage (Category 1), or

— the substance is spontaneously flammable in air or in contact with water or moisture at room temperature.

8.2.1.  Serious eye damage/eye irritation, in vitro

►M64  
8.2.1.  If results from a first in vitro study do not allow a conclusive decision on the classification of a substance or on the absence of eye irritation potential, (an)other in vitro study/studies for this endpoint shall be performed by the registrant or may be required by the Agency.  ◄

▼M42

8.3.  Skin sensitisation

Information allowing:

— a conclusion whether the substance is a skin sensitiser and whether it can be presumed to have the potential to produce significant sensitisation in humans (Cat. 1A), and

— risk assessment, where required.

The study(ies) under point 8.3.1 and 8.3.2 do not need to be conducted if:

— the substance is classified as skin corrosion (Category 1), or

— the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5), or

— the substance is spontaneously flammable in air or in contact with water or moisture at room temperature.

8.3.1.  Skin sensitisation, in vitro/in chemico

Information from in vitro/in chemico test method(s) recognised according to Article 13(3), addressing each of the following key events of skin sensitisation:

(a)  molecular interaction with skin proteins;

(b)  inflammatory response in keratinocytes;

(c)  activation of dendritic cells.

The(se) test(s) do not need to be conducted if:

— an in vivo study according to point 8.3.2 is available, or

— the available in vitro/in chemico test methods are not applicable for the substance or are not adequate for classification and risk assessment according to point 8.3.

If information from test method(s) addressing one or two of the key events in column 1 already allows classification and risk assessment according to point 8.3, studies addressing the other key event(s) need not be conducted.

8.3.2.  Skin sensitisation, in vivo

An in vivo study shall be conducted only if in vitro/in chemico test methods described under point 8.3.1 are not applicable, or the results obtained from those studies are not adequate for classification and risk assessment according to point 8.3.

The murine local lymph node assay (LLNA) is the first-choice method for in vivo testing. Only in exceptional circumstances should another test be used. Justification for the use of another in vivo test shall be provided.

In vivo skin sensitisation studies that were carried out or initiated before 10 May 2017, and that meet the requirements set out in Article 13(3), first subparagraph, and Article 13(4) shall be considered appropriate to address this standard information requirement.

▼C1

8.4.  Mutagenicity

►M70  
8.4.  In case of a positive result in the in vitro gene mutation study in bacteria referred to in point 8.4.1 of this Annex, which gives rise to concern, the registrant shall perform an in vitro study referred to in Annex VIII, point 8.4.2. Based on the positive result of any of those in vitro genotoxicity studies, the registrant shall propose, or the Agency may require, an appropriate in vivo study referred to in Annex IX, point 8.4.4. The in vivo study shall address the chromosomal aberration concern or the gene mutation concern or both, as appropriate.
The in vitro gene mutation study in bacteria does not need to be conducted if this test is not applicable for the substance. In this case, the registrant shall provide a justification and perform an in vitro study referred to in Annex VIII, point 8.4.3. In case of a positive result in that study the registrant shall perform an in vitro cytogenicity study referred to in Annex VIII, point 8.4.2. Based on the positive result in any of those in vitro genotoxicity studies, or in case one of the Annex VIII in vitro tests is not applicable for the substance, the registrant shall propose, or the Agency may require, an appropriate in vivo study referred to in Annex IX, point 8.4.4. The in vivo study shall address the chromosomal aberration concern or the gene mutation concern or both, as appropriate.
The in vitro gene mutation study in bacteria referred to in point 8.4.1 and follow-up testing do not need to be conducted in any of the following cases:

— the substance is known to cause germ cell mutagenicity, meeting the criteria for classification in the hazard class germ cell mutagenicity category 1A or 1B, and appropriate risk management measures are implemented,

— the substance is known to be a genotoxic carcinogen, meeting the criteria for classification both in the hazard class germ cell mutagenicity category 1A, 1B or 2 and in the hazard class carcinogenicity category 1A or 1B, and appropriate risk management measures are implemented.

 ◄

▼M51

8.4.1.  In vitro gene mutation study in bacteria

►M70  
8.4.1.  The in vitro gene mutation study in bacteria does not need to be conducted for nanoforms where it is not appropriate. In such case, an in vitro study referred to in Annex VIII, point 8.4.3, shall be provided.  ◄

▼C1

8.5.  Acute toxicity

8.5.  The study/ies do(es) not generally need to be conducted if:

— the substance is classified as corrosive to the skin.

▼M51

8.5.1.  By oral route

8.5.1.  The study need not be conducted if

a study on acute toxicity by the inhalation route (8.5.2) is available.

For nanoforms, a study by the oral route shall be replaced by a study by the inhalation route (8.5.2), unless exposure of humans via inhalation is unlikely, taking into account the possibility of exposure to aerosols, particles or droplets of an inhalable size.

▼C1

Source: Content sourced from EUR-Lex and licensed under CC BY 4.0. This is an unofficial presentation; only the official EUR-Lex version is legally authentic.

Screen documents for chemicals